Luteinizing Hormone (Lutropin)

A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.

Also Known As:

Networked: 2148 relevant articles (30 outcomes, 154 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Smith, Mark A: 11 articles (07/2014 - 11/2002)
2.	Atwood, Craig S: 9 articles (04/2008 - 11/2002)
3.	Perry, George: 9 articles (12/2007 - 11/2002)
4.	Casadesus, Gemma: 8 articles (07/2014 - 04/2005)
5.	Bowen, Richard L: 8 articles (12/2007 - 11/2002)
6.	Martins, Ralph N: 7 articles (11/2015 - 11/2002)
7.	Huhtaniemi, Ilpo: 7 articles (03/2014 - 05/2005)
8.	Veldhuis, Johannes D: 7 articles (09/2011 - 04/2002)
9.	Webber, Kate M: 7 articles (12/2007 - 04/2005)
10.	Verdile, Giuseppe: 6 articles (11/2015 - 05/2004)

Related Diseases

1.	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 09/01/1999 - "Hospital based studies have shown that oligomenorrhoeic adolescents have high luteinizing hormone (LH) and androgen concentrations, endocrine signs of polycystic ovary syndrome (PCOS). " 06/01/2014 - "Acupuncture may affect the hypothalamus pituitary axis and reduce the release of the luteinizing hormone in the treatment of polycystic ovary syndrome. " 01/01/2014 - "Adrenocortical production is associated with higher levels of luteinizing hormone in nonobese women with polycystic ovary syndrome." 02/15/2012 - "Abnormal luteinizing hormone (LH) secretion and action are known to affect ovarian steroidogenesis and thus playing a crucial role in manifestation of polycystic ovary syndrome (PCOS). " 02/15/2012 - "Role of luteinizing hormone β-subunit gene variants among South Indian women with polycystic ovary syndrome."
2.	Prostatic Neoplasms (Prostate Cancer) 03/01/2011 - "Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population." 06/01/2011 - "Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer." 03/01/2011 - "To evaluate Luteinizing hormone (LH) physiopathology along the pituitary testicular prostate axis at the time of initial diagnosis of prostate cancer in relation to the available clinical variables and to the subsequent cluster selection of the patient population. " 01/01/2009 - "[Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate]." 06/15/2003 - "Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer."
3.	Body Weight (Weight, Body) 09/01/2013 - "After 48 days of treatment, sperm concentrations were (87.85 +/- 28.44), (7.11 +/- 2.15), (35.98 +/- 14.04), (32.65 +/- 11.80) and (33.51 +/- 13.26) x 10(6)/ml in the blank control, infertile model, high-dose YJF, mid-dose YJF, and low-dose YJF groups, respectively; sperm motilities were (52.79 +/- 16.43), (31.14 +/- 3.07), (45.88 +/- 16.97), (51.56 +/- 13.35) and (49.53 +/- 10.16)%; the T levels were (194.07 +/- 40.29), (61.27 +/- 13.70), (121.87 +/- 24.35), (127.44 +/- 19.38) and (127.81 +/- 20.28) nmol/L; the luteinizing hormone (LH) levels were (7.017 +/- 0.269), (6.117 +/- 0.894), (7.060 +/- 0.871), (7.156 +/- 0.937) and (6.967 +/- 0.778) IU/L; the testis volumes were (3.775 +/- 0.183), (2.865 +/- 0.258), (3.236 +/- 0.058), (3.457 +/- 0.066) and (3.398 +/- 0.091) g; the epididymis volumes were (1.119 +/- 0.116), (0.833 +/- 0.226), (1.124 +/- 0.104), (1.132 +/- 0.107) and (1.114 +/- 0.106) g; the prostate volumes were (176.75 +/- 427.09), (131.67 +/- 39.45), (178.70 +/- 37.97), (180.11 +/- 37.39) and (179.00 +/- 35.42) mg; and the body weights were (188.50 +/- 7.12), (189.92 +/- 6.67), (187.42 +/- 5.47), (189.17 +/- 6.19) and (188.75 +/- 6.12) g. " 09/01/2013 - "Alarin was shown to stimulate food intake, increase body weight, induce luteinizing hormone secretion and stimulate fos-expression in rats; the anatomical localization for these functions correlates well with the varied distribution of the alarin peptide in the brain. " 04/01/2012 - "Effects of alarin on food intake, body weight and luteinizing hormone secretion in male mice." 08/01/2008 - "Using an enzyme-linked immunosorbent assay (ELISA), we found a significant decrease in levels of plasma luteinizing hormone (LH) at a dose of 3.0 mg/kg body weight. " 08/01/2005 - "In male rodents and primates, intracerebroventricular (icv) infusions of GALP stimulate luteinizing hormone (LH) release, induce Fos expression in brain areas implicated in feeding and reproduction, and affect food intake and body weight in rodents. "
4.	Infertility (Sterility) 01/01/1998 - "A spontaneous luteinizing hormone surge is beneficial in women with unexplained infertility undergoing controlled ovarian hyperstimulation without in vitro fertilization." 04/01/1989 - "A prospective randomized study was conducted in 47 couples with infertility due to subnormal semen to compare luteinizing hormone (LH)-timed intrauterine insemination with LH-timed natural intercourse. " 01/01/2015 - "However, this treatment can result in luteinizing hormone suppression which, in turn, can lead to reduced sperm numbers and infertility, making TRT inappropriate for men who wish to father children. " 01/01/2014 - "The steroidogenesis of the CL is dependent on continued tonic luteinizing hormone (LH) secretion (Fritz and Speroff, Clinical gynecologic endocrinology and infertility, 8th edn. " 09/01/2010 - "Predictive factors evaluated were female age, duration of infertility, indication for IUI, number of preovulatory follicles, luteinizing hormone level on day of trigger and postwash total motile fraction (TMF). "
5.	Spontaneous Abortion (Miscarriage) 06/01/1991 - "It remains to be elucidated if this therapy, followed by decreased luteinizing hormone, is effective in reducing the elevated risk of miscarriages in women with PCOS." 11/01/1996 - "Several studies have shown that high concentrations of luteinizing hormone (LH) in the follicular phase of stimulation can have a negative effect on oocyte quality, pregnancy rate and incidence of miscarriage. " 12/01/2009 - "The ideal time for implantation is 6-10 days after the luteinizing hormone (LH) surge; implantation occurring outside this optimal window is associated with a higher likelihood of miscarriage. " 10/01/1998 - "Because the biological and clinical significance of a genetic variant of luteinizing hormone (LH) is unclear, we therefore evaluated the occurrence of variant LH in women with a history of recurrent spontaneous abortion (RSA) and related it to specific LH concentrations, luteal function and pregnancy outcome. " 05/01/1995 - "Our objective was to test the hypothesis that the association between elevated luteinizing hormone (LH) concentrations and miscarriage is mediated via an effect of LH on the maternal environment, rather than on the oocyte. "

Related Drugs and Biologics

1.	Follicle Stimulating Hormone (Follitropin)
2.	Testosterone (Sustanon)
3.	Prolactin
4.	Gonadotropin-Releasing Hormone (GnRH)
5.	Estradiol (Estrace)
6.	Progesterone
7.	Insulin (Novolin)
8.	Hormones
9.	LH Receptors (LH Receptor)
10.	Gonadotropins

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
3.	Orchiectomy (Orchidectomy)
4.	Injections
5.	Drug Therapy (Chemotherapy)